Thyroid Cancer

Lenvatinib Could Be a New Option for Patients with Differentiated Radioiodine-Resistant Thyroid Cancer

ASCO Annual Meeting
May 31, 2014

Results from a recent study show that the drug lenvatinib could become a new, effective treatment option for patients with differentiated thyroid cancer that is resistant to standard radioiodine (RAI) therapy. Differentiated thyroid cancer is the most common subtype of thyroid cancer. It is generally curable with surgery and RAI. However, about 5% to 15% of patients with this subtype develop resistance to RAI, which means that it is no longer able to control the cancer’s growth.

Sorafenib Stops Growth of Thyroid Cancer When Radioactive Iodine Has Stopped Working

ASCO Annual Meeting
June 2, 2013

In a recent study, researchers found that the drug sorafenib (Nexavar) keeps metastatic differentiated thyroid cancer from worsening when treatment with radioactive iodine has stopped working. Differentiated thyroid cancer is the most common type of thyroid cancer; it is called “differentiated” because the cancerous thyroid cells look like normal thyroid cells when viewed under a microscope. Metastatic cancer means the thyroid cancer has spread outside of the thyroid.

Subscribe to RSS - Thyroid Cancer